Ardelyx Appoints Sue Hohenleitner as Chief Financial Officer
Ardelyx, Inc. (NASDAQ: ARDX), a biopharmaceutical company dedicated to developing innovative medicines for significant medical needs, has made a pivotal addition to its leadership team with the appointment of Sue Hohenleitner as Chief Financial Officer (CFO). With an impressive background spanning over three decades in corporate finance, strategic planning, and investor relations, Ms. Hohenleitner steps into the role on November 4, 2025, following the company's third-quarter financial reporting.
Expertise and Leadership Experience
Ms. Hohenleitner brings a wealth of experience from her previous role as Vice President and CFO of Johnson & Johnson (J&J) Innovative Medicine North America. Here, she demonstrated her ability to lead financial strategies effectively for a substantial $36 billion commercial enterprise. Her deep understanding of finance and operations within various therapeutic areas positions her well to guide Ardelyx’s financial journey.
Driving Growth and Innovation
Mike Raab, president and CEO of Ardelyx, emphasized the excitement surrounding Ms. Hohenleitner's appointment by noting her visionary approach and proven track record in executing growth strategies. Her ability to foster operational excellence is expected to enhance Ardelyx’s momentum and long-term success. Under her leadership, the company aims to deliver significant value to patients and stakeholders alike.
Ms. Hohenleitner’s Vision for Ardelyx
Expressing her enthusiasm for joining Ardelyx, Ms. Hohenleitner stated, “I am very excited to join Ardelyx at this important time in its evolution. With two first-in-class medicines already on the market and plans for future expansion, I look forward to collaborating with the team to develop new strategic paths for growth and innovation.”
A Proven Track Record at J&J
Throughout her 28-year tenure at J&J, Ms. Hohenleitner led multiple finance organizations across various domains, including supply chain management, commercial ventures, and business development. Her significant contributions led to improved efficiencies and enhanced funding for growth initiatives. Notably, she played a crucial role in the successful acquisition of two major deals that led to groundbreaking product launches.
Education and Recognition
Ms. Hohenleitner is a Certified Public Accountant in Pennsylvania and holds certifications as a Certified Management Accountant. She earned her Bachelor of Science in Accounting from La Salle University, followed by a Master of Business Administration from Villanova University. Her accomplishments in the finance sector have also earned her recognition as a Top 25 CFO in Biotech.
Ardelyx’s Commitment to Innovation
Founded with the mission to create first-in-class medicines addressing critical medical needs, Ardelyx is currently making waves in the industry with its approved products, IBSRELA and XPHOZAH. The company has established partnerships for the development and commercialization of its lead compound, tenapanor, enriching its portfolio in various international markets.
Conclusion
The addition of Sue Hohenleitner as CFO marks a significant milestone in Ardelyx's aspirations for growth and innovation. As the company looks ahead, her leadership will be crucial in navigating the evolving landscape of biopharmaceuticals and in boosting financial performance. The team at Ardelyx is poised to strengthen its operations and expand its product offerings, ultimately benefiting patients who rely on their groundbreaking treatments.
Frequently Asked Questions
Who is Sue Hohenleitner?
Sue Hohenleitner is the newly appointed Chief Financial Officer of Ardelyx, bringing over 30 years of experience in finance and strategic planning.
What was Ms. Hohenleitner's previous role?
She was the Vice President and CFO at Johnson & Johnson Innovative Medicine North America before joining Ardelyx.
When will Ms. Hohenleitner officially start her role at Ardelyx?
She will assume her role as CFO on November 4, 2025, following the third-quarter financial reporting.
What are the main products offered by Ardelyx?
Ardelyx currently has two approved products in the United States: IBSRELA and XPHOZAH, both of which utilize the innovative compound tenapanor.
Why is Sue Hohenleitner's appointment significant?
Her extensive background in financial leadership is expected to bolster Ardelyx’s growth strategies and enhance its market position.
